Please type a plus sign (+) inside this box →	—	
	1 T 1	

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substit	Substitute for form 1449A/PTO		Complete if Known				
		DIGGL COURT	Application Number				
-		DISCLOSURE	Filing Date	01/09/2002	-		
STA	STATEMENT BY APPLICANT		First Named Inventor	Anne Chew			
			Group Art Unit	1632	7		
	(use as many she	ets as necessary)	Examiner Name	Joseph Woitach	# 4.		
Sheet	1	of 1	Attorney Docket Number	MWH-0001US	G. S.		
					54		

				U.S. PATENT DOC	UMENTS		000
Examiner Initials*	Cite No.1	Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	D C
				- <u> </u>			
							
	·				 	· ····································	
			-++				
 							
					 		
- 				·-····································	 		
·				· ····			
						· · · · · · · · · · · · · · · · · · ·	
							
-				· · · · · · · · · · · · · · · · · · ·			
					+		
i	ı		1 1				

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner	Cite		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Γ
Initials*	No.1	Office ³	Number4	Kind Code ⁵ (<i>if known</i>)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T
	ĀA	wo	01/04137	A1	Genaissance Pharma	01/18/2001	entire document	Ţ
								1
		 						╀
		\vdash				 	,	+-
								L
								╀-
						-		╀

Examiner		Date	
Signature	·_ ·	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a	plus s	sign (+)	inside thi	s box	→	+
riease type a	pius s	sign (r)	maide un	3 00	~	+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Compl te if Known			
•			Application Number		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	01/09/2002	
			First Named Inventor	Anne Chew	
SIA	I LIVILIA I DI	ALLEGAN	· Group Art Unit	1632	
	(use as many sheets	s as necessary)	Examiner Name	Joseph Woitach	
Sheet	1 of	2	Attorney Docket Number	MWH-0001US	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BA	AKATSU T et al., "Osteoclastogenesis Inhibitory Factor Exhibits Hypocalcemic Effects in Normal Mice and in Hypercalcemic Nude Mice Carrying Tumors Associated With Humoral Hypercalcemia of Malignancy," Bone Vol., 23 (6) p 495-498 (December 1998).	
	BB	CHAMBERS TJ, "Regulation of the differentiation and function of osteoclasts," J. Pathology, September 2000 Vol 192 (1) p 4-13.	
	ВС	LACEY DL et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," Cell, 17 April 1998 Vol 93 (2) p.165-76.	
	BD	MIZUNO A et al., "Severe Osteoporosis in Mice Lacking Osteoclastogenesis Inhibitory Factor/Osteoprotegerin," Biochem. Biophys. Res. Comm., Vol 247, p 610-615 (1998).	
	BE	MORINAGA T et al., "Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis inhibitory factor," Eur. J. Biochem, 1998 Vol 254 (3) p 685-91.	
	BF	SIMONET WS et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," Cell, 18 April 1997 Vol 89 (2) p 309-19.	
	BG	TAKAHASHI N et al., "A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, regulates Osteoclast Differentiation and Function," Biochem. Biophys. Res. Comm. Vol 256, p 449-455 (1999).	
	ВН	TOMOYASU A et al., "Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor," Biochem. Biophys. Res. Comm. 1998 Vol 245 (2) p. 382-7.	
	BI	YAMAGUCHI K et al., "Characterization of structural domains of human osteoclastogenesis inhibitory factor," J. Biol. Chem., 27 February 1998 Vol 273 (9) p. 5117-23.	
	Bl	YASUDA H et al., "Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro," Endocrinology March 1998 Vol 139 (3) p 1329-37.	
	BK	Database Genbank, National Center for Biotechnology Information, a division of the National Library of Medicine, Accession No. U94332, May 1997.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a	plus	sign (+)	inside	this	box	→	+

Please type a plus sign (+) inside this box

+ Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Compl te if Known			
INFORMATION BIRDS COLUMN				Application Number			
INFORMATION DISCLOSURE		Filing Date	01/09/2002				
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Anne Chew		
				Group Art Unit	1632		
	(use as many sheets as necessary)		Examiner Name	Joseph Woitach			
Sheet	2	of	2	Attorney Docket Number	MWH-0001US		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BL	Database Genbank, National Center for Biotechnology Information, a division of the National Library of Medicine, Accession No. U94331, May 1997.	
Examiner	T	Date	

1	Examiner	Date	
1	Signature	Considered	
•			

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not * considered. Include copy of this form with next communication to applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: application of Chew, Anne et al.

for HAPLOTYPES OF THE TNFRSF11A GENE

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

CERTIFICATION UNDER 37 C.F.R. SECTION 1.10*

(Express Mail label number is mandatory.)
(Express Mail certification is optional.)

hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the Unit
hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the Unit States Postal Service on, 2002 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO
states i ostal service on, 2002 (date), ill all envelope as EAPRESS WAIL FOST OFFICE TO
ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EL594656967US addressed to Assistant
Commissioner for Patents, Washington, D.C. 20231. Nathaniel D. Judish

MWH-0001US

Transmittal of Information Disclosure Statement within 3 months

Reg. No.: 47,934 Tel. No.: 203-786-3468 Customer No.: 25106

Signature of Practitioner

Sandra L. Shaner

Genaissance Pharmaceuticals, Inc.

Five Science Paerk New Haven, CT 06511